<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Saxagliptin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Saxagliptin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Saxagliptin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12221" href="/d/html/12221.html" rel="external">see "Saxagliptin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7997762"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Onglyza</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52870864"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Saxagliptin;</li>
<li>Onglyza;</li>
<li>SANDOZ Saxagliptin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8008270"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F8008346"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>May require a dose reduction of insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinides) to avoid hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37150579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37150579'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed <b>or</b> who cannot take metformin, particularly in patients close to glycemic goals when avoidance of hypoglycemia and/or weight gain is desirable. Use <b>has not been</b> associated with improved cardiovascular (CV) or renal outcomes; use <b>has been</b> associated with an increased risk of heart failure hospitalization in patients with CV disease or multiple CV risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.2','lexi-content-ref-23992601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.2','lexi-content-ref-23992601'])">Ref</a></span>). Due to lack of additive glycemic benefit, avoid use in combination with glucagon-like peptide-1 receptor agonist-based therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37150579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37150579'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2.5 to 5 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990446"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥45 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;45 mL/minute/1.73 m<sup>2</sup>: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">ESRD requiring hemodialysis: 2.5 mg once daily; administer postdialysis</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50987647"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Mild to severe impairment: No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F8008347"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56319165"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Arthralgia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Arthralgia</b>, including severe and disabling cases, has been reported with dipeptidyl peptidase-4 (DPP-4) inhibitors, including saxagliptin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.3','lexi-content-ref-26873369','lexi-content-ref-28778563','lexi-content-ref-32015789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.3','lexi-content-ref-26873369','lexi-content-ref-28778563','lexi-content-ref-32015789'])">Ref</a></span>). Specific inflammatory joint complications with DPP-4 inhibitors may include polyarthritis, polyarthropathy, rheumatoid arthritis, and severe synovitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23462883','lexi-content-ref-31444259','lexi-content-ref-23937822','lexi-content-ref-Sasaki.1','lexi-content-ref-30724413','lexi-content-ref-22275459','lexi-content-ref-22864134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23462883','lexi-content-ref-31444259','lexi-content-ref-23937822','lexi-content-ref-Sasaki.1','lexi-content-ref-30724413','lexi-content-ref-22275459','lexi-content-ref-22864134'])">Ref</a></span>). Patients may or may not exhibit an increase in rheumatoid factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31149299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31149299'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not well established; one hypothesis includes cytokine-induced inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26873369','lexi-content-ref-29468916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26873369','lexi-content-ref-29468916'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; onset may occur within 1 day to years after treatment initiation. Symptoms may resolve with discontinuation of therapy. Some patients may experience a recurrence of symptoms if DPP-4 inhibitor therapy resumes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">In one study, most patients who reported arthralgias did so within 3 months of initiation of DPP-4 inhibitors and symptoms resolved within 1 month after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30724413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30724413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy; data are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27127847','lexi-content-ref-24919467','lexi-content-ref-28778563','lexi-content-ref-30724413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27127847','lexi-content-ref-24919467','lexi-content-ref-28778563','lexi-content-ref-30724413'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl peptidase-4 (DPP-4) inhibitor use, including saxagliptin, has been associated with development or exacerbation of <b>bullous pemphigoid</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27031194','lexi-content-ref-29682739','lexi-content-ref-34287770','lexi-content-ref-32236820','lexi-content-ref-32741073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27031194','lexi-content-ref-29682739','lexi-content-ref-34287770','lexi-content-ref-32236820','lexi-content-ref-32741073'])">Ref</a></span>). Although most DPP-4 inhibitors have been associated with the development of bullous pemphigoid, vildagliptin is associated with a higher risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27031194','lexi-content-ref-34287770','lexi-content-ref-30624566','lexi-content-ref-31215644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27031194','lexi-content-ref-34287770','lexi-content-ref-30624566','lexi-content-ref-31215644'])">Ref</a></span>). In addition, severe cutaneous adverse reactions (SCARs) (eg, exfoliative skin conditions) have been reported with saxagliptin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32938499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32938499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic</p>
<p style="text-indent:-2em;margin-left:6em;">Bullous pemphigoid: Exact mechanism unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27031194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27031194'])">Ref</a></span>). Some skin cells (including keratinocytes) express DPP-4, leading to an increase in cytokine production, tissue differentiation, and collagen metabolism; whether this leads to an alteration in the properties of the epidermal basement membrane is unknown.</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions (including SCARs): Mediated by T-cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Bullous pemphigoid: Delayed; median onset of ~6 months (range: 6 to 1,751 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30575097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30575097'])">Ref</a></span>). Most cases of bullous pemphigoid typically resolve following discontinuation; some require symptomatic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27031194','lexi-content-ref-29682739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27031194','lexi-content-ref-29682739'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions: Varied; typically occur days to weeks after drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age; although older age may be a risk factor for the development of bullous pemphigoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30002201','lexi-content-ref-29274348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30002201','lexi-content-ref-29274348'])">Ref</a></span>), some studies have not shown age to be a factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30624566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30624566'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males; some studies have suggested that male patients with diabetes may be at higher risk than female patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30624566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30624566'])">Ref</a></span>), although a meta-analysis of case-controlled studies did not find sex to be a predisposing risk factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31215644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31215644'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Heart failure</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">An increased risk of hospitalization due to <b>heart failure</b> (HF) was identified as a potential issue with dipeptidyl peptidase-4 (DPP-4) inhibitors, specifically saxagliptin and alogliptin, following results from the SAVOR TIMI 53 and EXAMINE trials, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>). The SAVOR TIMI 53 trial showed that the overall incidence of hospitalization for HF was greater in the saxagliptin arm compared to placebo (3.5% vs 2.8%; p=0.007); in a multivariable analysis of the data, the strongest association with hospitalization for HF regardless of treatment group was previous HF and preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23992601','lexi-content-ref-25189213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23992601','lexi-content-ref-25189213'])">Ref</a></span>). In contrast, the TECOS and CARMELINA trials showed no increased risk of hospitalization due to HF with sitagliptin or linagliptin, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26052984','lexi-content-ref-32206483','lexi-content-ref-27437883','lexi-content-ref-30586723','lexi-content-ref-30418475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26052984','lexi-content-ref-32206483','lexi-content-ref-27437883','lexi-content-ref-30586723','lexi-content-ref-30418475'])">Ref</a></span>). A meta-analysis of 182 trials found that, overall, use of a DPP-4 inhibitor was not associated with an increased risk of HF (OR: 1.05; 95% CI: 0.96 to 1.15; I<sup>2</sup> = 0%); however, a significantly higher risk of HF was seen with saxagliptin (OR: 1.22; 95% CI: 1.03 to 1.45), but not for other DPP-4 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34364771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34364771'])">Ref</a></span>). The American Diabetes Association recommends avoiding use of saxagliptin in patients with HF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1'])">Ref</a></span>); the American Heart Association (AHA) considers saxagliptin to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: major) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586788']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586788'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Variable; the AHA suggests the impact of DPP-4 inhibitors on myocardial dysfunction may be seen within weeks to ≥1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for HF or preexisting HF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1','lexi-content-ref-25189213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1','lexi-content-ref-25189213'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25189213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25189213'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis</b> and <b>angioedema</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28539578','lexi-content-ref-24376173','lexi-content-ref-32938499','lexi-content-ref-24493030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28539578','lexi-content-ref-24376173','lexi-content-ref-32938499','lexi-content-ref-24493030'])">Ref</a></span>). Vildagliptin may be associated with higher risk of angioedema than other DPP-4 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23323612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23323612'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic</p>
<p style="text-indent:-2em;margin-left:6em;">Angioedema: Considered a non–mast-cell-mediated process involving impaired catabolism of bradykinin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21530877']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21530877'])">Ref</a></span>). Saxagliptin and other dipeptidyl peptidase-4 (DPP-4) inhibitors can inactivate substance P and bradykinin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22826453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22826453'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Anaphylaxis: Considered to be an IgE-mediated reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; events have generally been noted within the first 3 months of therapy and may occur with the initial dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19581505','lexi-content-ref-24324987','lexi-content-ref-28539578','lexi-content-ref-20536525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19581505','lexi-content-ref-24324987','lexi-content-ref-28539578','lexi-content-ref-20536525'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hereditary angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28554195','lexi-content-ref-29723342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28554195','lexi-content-ref-29723342'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of angioedema with other DPP-4 inhibitors</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pancreatic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>acute pancreatitis</b> (including hemorrhagic and necrotizing with some fatalities), chronic pancreatitis, and pancreatic cancer have been reported with use of incretin-based therapies (eg, dipeptidyl peptidase-4 [DPP-4] inhibitors, glucagon-like peptide 1 [GLP-1] receptor agonists), including saxagliptin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31870827','lexi-content-ref-FDA.2','lexi-content-ref-24930656','lexi-content-ref-24914244','lexi-content-ref-29468916','lexi-content-ref-27659407']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31870827','lexi-content-ref-FDA.2','lexi-content-ref-24930656','lexi-content-ref-24914244','lexi-content-ref-29468916','lexi-content-ref-27659407'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Causality has not been firmly established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24571751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24571751'])">Ref</a></span>). DPP-4 inhibitors indirectly stimulate GLP-1 receptors in pancreatic islet beta cells and exocrine duct cells, which may cause an overgrowth of the cells that cover the smaller ducts, thereby resulting in hyperplasia, increased pancreatic weight, duct occlusion, back pressure, and subsequent acute or chronic pancreatic inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26537555','lexi-content-ref-25633664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26537555','lexi-content-ref-25633664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with a prior history of pancreatitis may be at an increased risk for acute pancreatitis.</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with acute pancreatitis due to any cause are at an increased risk for progression to recurrent acute pancreatitis and then to chronic pancreatitis; patients with chronic pancreatitis are at an increased risk for pancreatic cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23622135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23622135'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Risk factors for pancreatitis due to any cause include, but are not limited to, hypertriglyceridemia, cholelithiasis, alcohol use, and obesity.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8008284"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2%; including facial edema and urticaria)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure (FDA 2018a)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid (García-Díez 2018), exfoliative dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholecystitis (He 2022), pancreatitis (including acute pancreatitis) (Lee 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Thalha 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Hahn 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (including severe arthralgia) (Chaica-Brom 2013), rhabdomyolysis</p></div>
<div class="block coi drugH1Div" id="F8008277"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions) to saxagliptin or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to another DPP-4 inhibitor; diabetic ketoacidosis, diabetic coma/precoma, type 1 diabetes mellitus</p></div>
<div class="block war drugH1Div" id="F8008278"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery (Mechanick 2020; Melissas 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">– Glucagon-like peptide-1 exposure and therapeutic efficacy: Closely monitor for signs and symptoms of pancreatitis; gastric bypass and sleeve gastrectomy may increase endogenous secretion of glucagon-like peptide-1 (Korner 2009; Peterli 2012). A single-dose, placebo-controlled study evaluated short-term therapy (4 weeks) with sitagliptin in gastric bypass patients having persistent or recurrent type 2 diabetes and found it to be well tolerated and provided a small but significant reduction in postprandial blood glucose (Shah 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with moderate to severe renal dysfunction (eGFR &lt;45 mL/minute/1.73 m<sup>2</sup>) including end-stage renal disease requiring hemodialysis; dosing adjustment required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for use in patients with type 1 diabetes mellitus or with diabetic ketoacidosis.</p></div>
<div class="block foc drugH1Div" id="F8008385"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Onglyza: 2.5 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p></div>
<div class="block geq drugH1Div" id="F8008268"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322600"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Onglyza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $19.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $19.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (sAXagliptin HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $17.44 - $17.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $17.44 - $17.46</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52870865"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Onglyza: 2.5 mg, 5 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p></div>
<div class="block adm drugH1Div" id="F8008352"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals. Swallow whole; do not split or cut tablets.</p></div>
<div class="block meg drugH1Div" id="F13376319"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at http://www.azpicentral.com/onglyza/onglyza_med.pdf#page=1, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F8008272"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, type 2, treatment:</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus as monotherapy or combination therapy.</p></div>
<div class="block mst drugH1Div" id="F8008266"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">SAXagliptin may be confused with SITagliptin, SUMAtriptan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9837684"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F7998852"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Dipeptidyl Peptidase-IV Inhibitors may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of SAXagliptin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of SAXagliptin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of SAXagliptin. Management: Limit the saxagliptin dose to 2.5 mg daily when combined with strong CYP3A4 inhibitors. When using the saxagliptin combination products saxagliptin/dapagliflozin or saxagliptin/dapagliflozin/metformin, avoid use with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Insulins: Dipeptidyl Peptidase-IV Inhibitors may enhance the hypoglycemic effect of Insulins.  Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Dipeptidyl Peptidase-IV Inhibitors may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider a decrease in sulfonylurea dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56092104"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Dipeptidyl peptidase 4 (DPP-4) inhibitors are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)</p></div>
<div class="block pri drugH1Div" id="F8008274"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than saxagliptin are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).</p></div>
<div class="block brc drugH1Div" id="F16571115"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if saxagliptin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F8008351"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Individualized medical nutrition therapy based on American Diabetes Association recommendations is an integral part of therapy.</p></div>
<div class="block mop drugH1Div" id="F8008354"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Plasma glucose; renal function (prior to initiation of therapy and periodically thereafter); lymphocyte counts (if unusual or persistent infection); signs/symptoms of pancreatitis, heart failure, and/or bullous pemphigoid (eg, blisters or erosions).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F8008295"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults ( AACE [Samson 2023]; ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note:</b> Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 80 to 150 mg/dL (SI: 4.4 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F8008293"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Saxagliptin inhibits dipeptidyl peptidase 4 (DPP-4) enzyme resulting in prolonged active incretin levels. Incretin hormones (eg, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide) regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from pancreatic alpha cells. Decreased glucagon secretion results in decreased hepatic glucose production. Under normal physiologic circumstances, incretin hormones are released by the intestine throughout the day and levels are increased in response to a meal; incretin hormones are rapidly inactivated by the DPP-4 enzyme.</p></div>
<div class="block phk drugH1Div" id="F8008296"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Negligible</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4/5 to 5-hydroxy saxagliptin (active; ~50% potency of the parent compound)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Saxagliptin: 2.5 hours; 5-hydroxy saxagliptin: 3.1 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Saxagliptin: 2 hours; 5-hydroxy saxagliptin: 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (75%, 24% of the total dose as saxagliptin, 36% of the total dose as 5-hydroxy saxagliptin); feces (22%)</p></div>
<div class="block phksp drugH1Div" id="F51159869"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC was up to 2.1- and 4.5-fold higher in patients with moderate or severe renal impairment. Dosage adjustment is required. In patients with mild renal impairment, AUC for saxagliptin and its active metabolite were 20% and 70% higher, respectively, which is not considered significant.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: C<sub>max</sub> and AUC were 8% and 77% higher, respectively, in patients with hepatic impairment (Child-Pugh class A, B, and C). The corresponding C<sub>max</sub> and AUC of the active metabolite were 59% and 33% lower, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962012"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Sixtin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(CY)</span> <span class="country">Cyprus</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Formigliptin | Onglyza | Saxaptin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Saxagliptin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Onglyza | Riax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Onglyza | Saxagliptin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Onglyza | Saxagliptin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Gliplyza | Lyza | Saglip | Saxagen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Onglyza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370047">
<a name="29370047"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/29370047/pubmed" id="29370047" target="_blank">29370047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30461693">
<a name="30461693"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol. 2018;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30461693/pubmed" id="30461693" target="_blank">30461693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed October 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30002201">
<a name="30002201"></a>Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese Adverse Drug Event Report Database. <i>Diabetes Care</i>. 2018;41(9):e130-e132. doi:10.2337/dc18-0210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30002201/pubmed" id="30002201" target="_blank">30002201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28554195">
<a name="28554195"></a>Arcani R, Martinez S, Gayet S. Sitagliptin and angioedema. <i>Ann Intern Med</i>. 2017;167(2):142-143. doi:10.7326/L16-0649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/28554195/pubmed" id="28554195" target="_blank">28554195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27031194">
<a name="27031194"></a>Béné J, Moulis G, Bennani I, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. <i>Br J Dermatol</i>. 2016;175(2):296-301. doi:10.1111/bjd.14601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/27031194/pubmed" id="27031194" target="_blank">27031194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29274348">
<a name="29274348"></a>Benzaquen M, Borradori L, Berbis P, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. <i>J Am Acad Dermatol</i>. 2018;78(6):1090-1096. doi:10.1016/j.jaad.2017.12.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/29274348/pubmed" id="29274348" target="_blank">29274348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19581505">
<a name="19581505"></a>Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. <i>Hypertension</i>. 2009;54(3):516-523. doi:10.1161/HYPERTENSIONAHA.109.134197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/19581505/pubmed" id="19581505" target="_blank">19581505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21530877">
<a name="21530877"></a>Byrd JS, Minor DS, Elsayed R, Marshall GD. DPP-4 inhibitors and angioedema: a cause for concern? <i>Ann Allergy Asthma Immunol</i>. 2011;106(5):436-438. doi:10.1016/j.anai.2011.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/21530877/pubmed" id="21530877" target="_blank">21530877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23598537">
<a name="23598537"></a>Chaicha-Brom T, Yasmeen T. DPP-IV inhibitor-associated arthralgias. <i>Endocr Pract</i>. 2013;19(2):377. doi:10.4158/EP13076.LT<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/23598537/pubmed" id="23598537" target="_blank">23598537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23462883">
<a name="23462883"></a>Crickx E, Marroun I, Veyrie C, et al. DPP4 inhibitor-induced polyarthritis: a report of three cases. <i>Rheumatol Int</i>. 2014;34(2):291-292. doi:10.1007/s00296-013-2710-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/23462883/pubmed" id="23462883" target="_blank">23462883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31870827">
<a name="31870827"></a>Dicembrini I, Montereggi C, Nreu B, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patientes treated with dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. <i>Diabetes Res Clin Pract</i>. 2020;159:107981. doi:10.1016/j.diabres.2019.107981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/31870827/pubmed" id="31870827" target="_blank">31870827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24571751">
<a name="24571751"></a>Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment [published correction appears in <i>N Engl J Med</i>. 2014;370(23):2253]. <i>N Engl J Med</i>. 2014;370(9):794-797. doi:10.1056/NEJMp1314078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/24571751/pubmed" id="24571751" target="_blank">24571751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration. FDA drug safety communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Updated March 7, 2018. Accessed October 28, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration. FDA drug safety communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Updated February 21, 2018. Accessed October 28, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-investigating-reports-possible-increased-risk-pancreatitis-and-pre</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.3">
<a name="FDA.3"></a>Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Updated June 23, 2016. Accessed October 28, 2021. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24324987">
<a name="24324987"></a>Gabb G, Andrew N. Lump in the throat - a case study. <i>Aust Fam Physician</i>. 2013;42(12):863-866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/24324987/pubmed" id="24324987" target="_blank">24324987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29682739">
<a name="29682739"></a>García-Díez I, Ivars-Lleó M, López-Aventín D, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization. <i>Int J Dermatol</i>. 2018;57(7):810-816. doi:10.1111/ijd.14005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/29682739/pubmed" id="29682739" target="_blank">29682739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29723342">
<a name="29723342"></a>Giavina-Bianchi P, Arruda LK, Aun MV, et al. Brazilian guidelines for hereditary angioedema management - 2017 update part 1: definition, classification and diagnosis. <i>Clinics (Sao Paulo)</i>. 2018;73:e310. doi:10.6061/clinics/2018/e310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/29723342/pubmed" id="29723342" target="_blank">29723342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22826453">
<a name="22826453"></a>Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. <i>Diabetes Care</i>. 2012;35(8):e60. doi:10.2337/dc12-0574<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/22826453/pubmed" id="22826453" target="_blank">22826453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26052984">
<a name="26052984"></a>Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes [published correction appears in <i>N Engl J Med</i>. 2015;373(6):586]. <i>N Engl J Med</i>. 2015;373(3):232-242. doi:10.1056/NEJMoa1501352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/26052984/pubmed" id="26052984" target="_blank">26052984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28539578">
<a name="28539578"></a>Hahn J, Trainotti S, Hoffmann TK, Greve J. Drug-induced inhibition of angiotensin converting enzyme and dipeptidyl peptidase 4 results in nearly therapy resistant bradykinin induced angioedema: a case report. <i>Am J Case Rep</i>. 2017;18:576-579. doi:10.12659/ajcr.901960<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/28539578/pubmed" id="28539578" target="_blank">28539578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35764326">
<a name="35764326"></a>He L, Wang J, Ping F, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. <i>BMJ</i>. 2022;377:e068882. doi:10.1136/bmj-2021-068882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/35764326/pubmed" id="35764326" target="_blank">35764326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24376173">
<a name="24376173"></a>Hirshberg B, Parker A, Edelberg H, Donovan M, Iqbal N. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. <i>Diabetes Metab Res Rev</i>. 2014;30(7):556-569. doi:10.1002/dmrr.2502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/24376173/pubmed" id="24376173" target="_blank">24376173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27127847">
<a name="27127847"></a>Hou WH, Chang KC, Li CY, Ou HT. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study. <i>Pain</i>. 2016;157(9):1954-1959. doi:10.1097/j.pain.0000000000000596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/27127847/pubmed" id="27127847" target="_blank">27127847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32938499">
<a name="32938499"></a>Huang J, Jia Y, Sun S, Meng L. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. <i>BMC Pharmacol Toxicol</i>. 2020;21(1):68. doi:10.1186/s40360-020-00447-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/32938499/pubmed" id="32938499" target="_blank">32938499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32206483">
<a name="32206483"></a>Inagaki N, Yang W, Watada H, et al. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA trial. <i>Diabetol Int</i>. 2019;11(2):129-141. doi:10.1007/s13340-019-00412-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/32206483/pubmed" id="32206483" target="_blank">32206483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34287770">
<a name="34287770"></a>Jedlowski PM, Jedlowski MF, Fazel MT. DPP-4 inhibitors and increased reporting odds of bullous pemphigoid: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. <i>Am J Clin Dermatol</i>. Published online July 21, 2021. doi:10.1007/s40257-021-00625-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/34287770/pubmed" id="34287770" target="_blank">34287770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(supp 4):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24919467">
<a name="24919467"></a>Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. <i>Ann Rheum Dis</i>. 2015;74(11):1968-1975. doi:10.1136/annrheumdis-2014-205216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/24919467/pubmed" id="24919467" target="_blank">24919467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23106132">
<a name="23106132"></a>Kirkman M, Briscoe VJ, Clark N, et al, "Diabetes in Older Adults: A Consensus Report," <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/23106132/pubmed" id="23106132" target="_blank">23106132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26537555">
<a name="26537555"></a>Knapen LM, van Dalem J, Keulemans YC, et al. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study. <i>Diabetes Obes Metab</i>. 2016;18(3):258-265. doi:10.1111/dom.12605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/26537555/pubmed" id="26537555" target="_blank">26537555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi: 10.1038/ijo.2009.79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24930656">
<a name="24930656"></a>Lee CF, Sun MS, Tai YK. Saxagliptin-induced recurrent acute pancreatitis. <i>Intern Med</i>. 2014;53(12):1351-1354. doi:10.2169/internalmedicine.53.1913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/24930656/pubmed" id="24930656" target="_blank">24930656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30624566">
<a name="30624566"></a>Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. <i>JAMA Dermatol</i>. 2019;155(2):172-177. doi:10.1001/jamadermatol.2018.4556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30624566/pubmed" id="30624566" target="_blank">30624566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34364771">
<a name="34364771"></a>Mannucci E, Nreu B, Montereggi C, et al. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. <i>Nutr Metab Cardiovasc Dis</i>. 2021;31(10):2745-2755. doi:10.1016/j.numecd.2021.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/34364771/pubmed" id="34364771" target="_blank">34364771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26873369">
<a name="26873369"></a>Mascolo A, Rafaniello C, Sportiello L, et al. Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. <i>Drug Saf</i>. 2016;39(5):401-407. doi:10.1007/s40264-016-0399-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/26873369/pubmed" id="26873369" target="_blank">26873369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586723">
<a name="30586723"></a>McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. <i>Circulation</i>. 2019;139(3):351-361. doi:10.1161/CIRCULATIONAHA.118.038352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30586723/pubmed" id="30586723" target="_blank">30586723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27437883">
<a name="27437883"></a>McGuire DK, Van de Werf F, Armstrong PW, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. <i>JAMA Cardiol</i>. 2016;1(2):126-135. doi:10.1001/jamacardio.2016.0103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/27437883/pubmed" id="27437883" target="_blank">27437883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160151">
<a name="23160151"></a>Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. <i>Ann Surg</i>. 2013;258(6):976-982. doi: 10.1097/SLA.0b013e3182774522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/23160151/pubmed" id="23160151" target="_blank">23160151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28778563">
<a name="28778563"></a>Men P, He N, Song C, Zhai S. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: a systematic review and meta-analysis. <i>Diabetes Metab</i>. 2017;43(6):493-500. doi:10.1016/j.diabet.2017.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/28778563/pubmed" id="28778563" target="_blank">28778563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24493030">
<a name="24493030"></a>Mikhail N. Effects of incretin-based therapy in patients with heart failure and myocardial infarction. <i>Endocrine</i>. 2014;47(1):21-28. doi:10.1007/s12020-014-0175-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/24493030/pubmed" id="24493030" target="_blank">24493030</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Onglyza (saxagliptin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2019.</div>
</li>
<li>
<div class="reference">
                  Onglyza (saxagliptin) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31444259">
<a name="31444259"></a>Padron S, Rogers E, Demory Beckler M, Kesselman M. DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis. <i>BMJ Case Rep</i>. 2019;12(8):e228981. doi:10.1136/bcr-2018-228981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/31444259/pubmed" id="31444259" target="_blank">31444259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31215644">
<a name="31215644"></a>Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: a systematic review and adjusted meta-analysis. <i>Australas J Dermatol</i>. 2020;61(1):e15-e21. doi:10.1111/ajd.13100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/31215644/pubmed" id="31215644" target="_blank">31215644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32015789">
<a name="32015789"></a>Rai P, Dwibedi N, Rowneki M, Helmer DA, Sambamoorthi U. Dipeptidyl peptidase-4 inhibitors and joint pain: a retrospective cohort study of older veterans with type 2 diabetes mellitus. <i>Am Health Drug Benefits</i>. 2019;12(5):223-231.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/32015789/pubmed" id="32015789" target="_blank">32015789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24914244">
<a name="24914244"></a>Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. <i>Diabetes Care</i>. 2014;37(9):2435-2441. doi:10.2337/dc13-2546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/24914244/pubmed" id="24914244" target="_blank">24914244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30418475">
<a name="30418475"></a>Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. <i>JAMA</i>. 2019;321(1):69-79. doi:10.1001/jama.2018.18269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30418475/pubmed" id="30418475" target="_blank">30418475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23323612">
<a name="23323612"></a>Saisho Y, Itoh H. Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? <i>Diabet Med</i>. 2013;30(4):e149-e150. doi:10.1111/dme.12134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/23323612/pubmed" id="23323612" target="_blank">23323612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23937822">
<a name="23937822"></a>Saito T, Ohnuma K, Suzuki H, et al. Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors. <i>Diabetes Res Clin Pract</i>. 2013;102(1):e8-e12. doi:10.1016/j.diabres.2013.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/23937822/pubmed" id="23937822" target="_blank">23937822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sasaki.1">
<a name="Sasaki.1"></a>Sasaki T, Hiki Y, Nagumo S, et al. Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus. <i>Diabetol Int</i>. 2010;1:90-92. doi:10.1007/s13340-010-0010-y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31149299">
<a name="31149299"></a>Sayiner ZA, Okyar B, Kısacık B, Akarsu E, Özkaya M, Araz M. DPP-4 inhibitors increase the incidence of arthritis/arthralgia but do not affect autoimmunity. <i>Acta Endocrinol (Buchar)</i>. 2018;14(4):473-476. doi:10.4183/aeb.2018.473<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/31149299/pubmed" id="31149299" target="_blank">31149299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29468916">
<a name="29468916"></a>Scheen AJ. The safety of gliptins : updated data in 2018. <i>Expert Opin Drug Saf</i>. 2018;17(4):387-405. doi:10.1080/14740338.2018.1444027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/29468916/pubmed" id="29468916" target="_blank">29468916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23992601">
<a name="23992601"></a>Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>N Engl J Med.</i> 2013;369(14):1317-1326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/23992601/pubmed" id="23992601" target="_blank">23992601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189213">
<a name="25189213"></a>Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. <i>Circulation</i>. 2014;130(18):1579-1588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/25189213/pubmed" id="25189213" target="_blank">25189213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29072800">
<a name="29072800"></a>Shah A, Levesque K, Pierini E, et al. Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery. <i>Diabetes Obes Metab</i>. 2018;20(4):1018-1023. doi: 10.1111/dom.13139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/29072800/pubmed" id="29072800" target="_blank">29072800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32236820">
<a name="32236820"></a>Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. <i>Endocrine</i>. 2020;69(3):504-507. doi:10.1007/s12020-020-02272-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/32236820/pubmed" id="32236820" target="_blank">32236820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20536525">
<a name="20536525"></a>Skalli S, Wion-Barbot N, Baudrant M, Lablanche S, Benhamou PY, Halimi S. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report. <i>Diabet Med</i>. 2010;27(4):486-487. doi:10.1111/j.1464-5491.2010.02973.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/20536525/pubmed" id="20536525" target="_blank">20536525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575097">
<a name="30575097"></a>Tanaka H, Ishii T. Analysis of patients with drug-induced pemphigoid using the Japanese Adverse Drug Event Report database. <i>J Dermatol</i>. 2019;46(3):240-244. doi:10.1111/1346-8138.14741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30575097/pubmed" id="30575097" target="_blank">30575097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30483596">
<a name="30483596"></a>Thalha AM, Mahadeva S, Boon Tan AT, Mun KS. Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease. <i>JGH Open</i>. 2018;2(5):242-245. doi:10.1002/jgh3.12083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30483596/pubmed" id="30483596" target="_blank">30483596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25633664">
<a name="25633664"></a>Thomsen RW, Pedersen L, Møller N, Kahlert J, Beck-Nielsen H, Sørensen HT. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. <i>Diabetes Care</i>. 2015;38(6):1089-1098. doi:10.2337/dc13-2983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/25633664/pubmed" id="25633664" target="_blank">25633664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27659407">
<a name="27659407"></a>Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. <i>Diabetes Care</i>. 2017;40(2):284-286. doi:10.2337/dc15-1707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/27659407/pubmed" id="27659407" target="_blank">27659407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30724413">
<a name="30724413"></a>Wang CY, Fu SH, Yang RS, Hsiao FY. Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: population-based cohort and nested case-control studies. <i>Pharmacoepidemiol Drug Saf</i>. 2019;28(4):500-506. doi:10.1002/pds.4733<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30724413/pubmed" id="30724413" target="_blank">30724413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23622135">
<a name="23622135"></a>Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. <i>Gastroenterology</i>. 2013;144(6):1252-1261. doi:10.1053/j.gastro.2013.01.068<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/23622135/pubmed" id="23622135" target="_blank">23622135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22275459">
<a name="22275459"></a>Yamauchi K, Sato Y, Yamashita K, et al. RS3PE in association with dipeptidyl peptidase-4 inhibitor: report of two cases. <i>Diabetes Care</i>. 2012;35(2):e7. doi:10.2337/dc11-1995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/22275459/pubmed" id="22275459" target="_blank">22275459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32741073">
<a name="32741073"></a>Yang W, Cai X, Zhang S, Han X, Ji L. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: a systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Metab Res Rev</i>. 2021;37(3):e3391. doi:10.1002/dmrr.3391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/32741073/pubmed" id="32741073" target="_blank">32741073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22864134">
<a name="22864134"></a>Yokota K, Igaki N. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report. <i>Intern Med</i>. 2012;51(15):2041-2044. doi:10.2169/internalmedicine.51.7592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/22864134/pubmed" id="22864134" target="_blank">22864134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586788">
<a name="30586788"></a>Zannad F, Rossignol P. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure. <i>Circulation</i>. 2019;139(3):362-365. doi:10.1161/CIRCULATIONAHA.118.038399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/saxagliptin-drug-information/abstract-text/30586788/pubmed" id="30586788" target="_blank">30586788</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9534 Version 290.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
